Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain
Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain
Intravenous immunoglobulin (IVIg) therapy is used to treat a wide range of autoimmune conditions and consists of pooled immunoglobulin G (IgG) from healthy donors. The immunosuppressive effects of IVIg are, in part, attributed to terminal α2,6-linked sialic acid residues on the N-linked glycans of the IgG Fc (fragment crystallizable) domain. This α2,6-sialylated Fc (sFc) has been reported to bind to the carbohydrate recognition domain (CRD) of the cell-surface lectin DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) and its murine orthologue SIGN-R1 (specific intracellular adhesion molecule-grabbing non-integrin R1) and, via this interaction, to signal the downstream expression of immunosuppressive cytokines and receptors. Consistent with this model, the antiinflammatory effect of IVIg treatment is abolished in a murine knock-out of SIGN-R1 and can be restored by a knock-in with human DC-SIGN. In contrast, however, existing glycan array and X-ray crystallographic studies indicate that the CRDs of both SIGN-R1 and DC-SIGN bind to a restricted set of primarily oligomannose-type glycans that does not include the glycans found on sFc. We attempted to reconcile these immunological and biophysical observations. We first generated hypersialylated, desialylated, deglycosylated and untreated serum IgG and found that the affinity for the complete extracellular region of the DC-SIGN tetramer was similar for all antibody glycoforms. Moreover, the binding could be attributed to cross-reactive, polyclonal Fab (fragment antigen-binding) specificities in serum as neither recombinant Fc nor sFc bound to DC-SIGN. In addition, serum IgG exhibited no competition against known ligands of the DC-SIGN CRD. These findings lead us to suggest that IVIg therapy does not involve binding of IgG Fc to DC-SIGN and that alternative cell-surface lectins are required for the antiinflammatory activity of sFc.
antibody, Fc, glycosylation, IVIg, sialic acid
1253-1258
Yu, Xiaojie
44d52374-eacc-4e23-b7da-c881e6d3a5dd
Vasiljevic, Snezana
17e075b4-520d-4b9b-a4a7-08ac394ae5e1
Mitchell, Daniel A.
d489622a-19e8-43a0-87cd-ba866f5212c2
Crispin, Matthew
cd980957-0943-4b89-b2b2-710f01f33bc9
Scanlan, Christopher N.
04dd1b57-b6fc-414c-8595-08310dbb3d32
26 April 2013
Yu, Xiaojie
44d52374-eacc-4e23-b7da-c881e6d3a5dd
Vasiljevic, Snezana
17e075b4-520d-4b9b-a4a7-08ac394ae5e1
Mitchell, Daniel A.
d489622a-19e8-43a0-87cd-ba866f5212c2
Crispin, Matthew
cd980957-0943-4b89-b2b2-710f01f33bc9
Scanlan, Christopher N.
04dd1b57-b6fc-414c-8595-08310dbb3d32
Yu, Xiaojie, Vasiljevic, Snezana, Mitchell, Daniel A., Crispin, Matthew and Scanlan, Christopher N.
(2013)
Dissecting the molecular mechanism of IVIg therapy: the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain.
Journal of Molecular Biology, 425 (8), .
(doi:10.1016/j.jmb.2013.02.006).
Abstract
Intravenous immunoglobulin (IVIg) therapy is used to treat a wide range of autoimmune conditions and consists of pooled immunoglobulin G (IgG) from healthy donors. The immunosuppressive effects of IVIg are, in part, attributed to terminal α2,6-linked sialic acid residues on the N-linked glycans of the IgG Fc (fragment crystallizable) domain. This α2,6-sialylated Fc (sFc) has been reported to bind to the carbohydrate recognition domain (CRD) of the cell-surface lectin DC-SIGN (dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin) and its murine orthologue SIGN-R1 (specific intracellular adhesion molecule-grabbing non-integrin R1) and, via this interaction, to signal the downstream expression of immunosuppressive cytokines and receptors. Consistent with this model, the antiinflammatory effect of IVIg treatment is abolished in a murine knock-out of SIGN-R1 and can be restored by a knock-in with human DC-SIGN. In contrast, however, existing glycan array and X-ray crystallographic studies indicate that the CRDs of both SIGN-R1 and DC-SIGN bind to a restricted set of primarily oligomannose-type glycans that does not include the glycans found on sFc. We attempted to reconcile these immunological and biophysical observations. We first generated hypersialylated, desialylated, deglycosylated and untreated serum IgG and found that the affinity for the complete extracellular region of the DC-SIGN tetramer was similar for all antibody glycoforms. Moreover, the binding could be attributed to cross-reactive, polyclonal Fab (fragment antigen-binding) specificities in serum as neither recombinant Fc nor sFc bound to DC-SIGN. In addition, serum IgG exhibited no competition against known ligands of the DC-SIGN CRD. These findings lead us to suggest that IVIg therapy does not involve binding of IgG Fc to DC-SIGN and that alternative cell-surface lectins are required for the antiinflammatory activity of sFc.
Text
2013-Dissecting the molecular mechanism of IVIg therapy the interaction between serum IgG and DC-SIGN is independent of antibody glycoform or Fc domain.
Restricted to Repository staff only
Request a copy
More information
e-pub ahead of print date: 13 February 2013
Published date: 26 April 2013
Keywords:
antibody, Fc, glycosylation, IVIg, sialic acid
Identifiers
Local EPrints ID: 414543
URI: http://eprints.soton.ac.uk/id/eprint/414543
ISSN: 0022-2836
PURE UUID: 239b8a2d-69ab-4c8d-976f-271218bddb30
Catalogue record
Date deposited: 03 Oct 2017 16:31
Last modified: 16 Mar 2024 04:30
Export record
Altmetrics
Contributors
Author:
Xiaojie Yu
Author:
Snezana Vasiljevic
Author:
Daniel A. Mitchell
Author:
Christopher N. Scanlan
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics